The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL(T315I) and exhibits a narrow resistance profile

Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABL(T315I) mutant is highly resistant to imatinib, nilotinib, and dasatinib and is frequently detected in relapsed pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Eide, Christopher A., Adrian, Lauren T., Tyner, Jeffrey W., Mac Partlin, Mary, Anderson, David J., Wise, Scott C., Smith, Bryan, Petillo, Peter A., Flynn, Daniel L., Deininger, Michael W.N., O’Hare, Thomas, Druker, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3206627/
https://ncbi.nlm.nih.gov/pubmed/21505103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-3224
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados